Bristol-Myers Squibb Company (BMY) 51.67 $BMY
Final Glance: Pharmaceuticals companies
AP - Mon Sep 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Midday Glance: Pharmaceuticals companies
AP - Mon Sep 22, 1:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Mon Sep 22, 10:05AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA
PR Newswire - Mon Sep 22, 8:51AM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
(NASDAQ: SIAL) concerning its proposed merger with Merck KGaA ("Merck" .
Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
Business Wire - Mon Sep 22, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease. The donations will fund the independent development of innovative educational materials about stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF). The materials, accessible to both patients and caregivers, will address disease awareness, identification of signs and symptoms, access to care, appropriate treatment options, shared decision making and medication adherence. National Stroke Association, Heart Rhythm Society, American College of Physicians, American Heart Association Founders Affiliate, Regents of the University of Michigan/Society for Vascular Medicine, WomenHeart and American College of Emergency Physicians will each receive a charitable donation to support their independent educational initiatives.
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Bristol-Myers Squibb (BMY) Approaches New Upside Target of $51.67
Comtex SmarTrend(R) - Fri Sep 19, 11:42AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $51.16 today and has reached the first level of resistance at $51.39. Analysts will be watching for a cross of the next upside pivot targets of $51.67 and $52.18.
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Frances K. Heller Rejoins Zafgen Board of Directors
GlobeNewswire - Thu Sep 18, 6:06AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Frances K. Heller will rejoin Zafgen's Board of Directors and will also be a member of the Audit Committee. Ms. Heller previously served as a Zafgen director from October 2011 to December 2013, and left the Board as she joined Bristol-Myers Squibb to lead its business development group. Zafgen's Board currently includes eight directors, seven of whom are independent.
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
Bristol-Myers Squibb Company 's board to pay dividends
M2 - Wed Sep 17, 6:36AM CDT
The board of directors of biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday declared a quarterly dividend of USD0.36 per share on the USD0.10 par value common stock.
Final Glance: Pharmaceuticals companies
AP - Mon Sep 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Midday Glance: Pharmaceuticals companies
AP - Mon Sep 22, 1:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Mon Sep 22, 10:05AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA
PR Newswire - Mon Sep 22, 8:51AM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
(NASDAQ: SIAL) concerning its proposed merger with Merck KGaA ("Merck" . Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
Business Wire - Mon Sep 22, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease. The donations will fund the independent development of innovative educational materials about stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF). The materials, accessible to both patients and caregivers, will address disease awareness, identification of signs and symptoms, access to care, appropriate treatment options, shared decision making and medication adherence. National Stroke Association, Heart Rhythm Society, American College of Physicians, American Heart Association Founders Affiliate, Regents of the University of Michigan/Society for Vascular Medicine, WomenHeart and American College of Emergency Physicians will each receive a charitable donation to support their independent educational initiatives.
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 4:40PM CDT
Bristol-Myers' (BMY) Yervoy gained Canadian approval for treating adults newly diagnosed with advanced melanoma.
Bristol-Myers Squibb (BMY) Approaches New Upside Target of $51.67
Comtex SmarTrend(R) - Fri Sep 19, 11:42AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $51.16 today and has reached the first level of resistance at $51.39. Analysts will be watching for a cross of the next upside pivot targets of $51.67 and $52.18.
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
Frances K. Heller Rejoins Zafgen Board of Directors
GlobeNewswire - Thu Sep 18, 6:06AM CDT
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Frances K. Heller will rejoin Zafgen's Board of Directors and will also be a member of the Audit Committee. Ms. Heller previously served as a Zafgen director from October 2011 to December 2013, and left the Board as she joined Bristol-Myers Squibb to lead its business development group. Zafgen's Board currently includes eight directors, seven of whom are independent.
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
Bristol-Myers Squibb Company 's board to pay dividends
M2 - Wed Sep 17, 6:36AM CDT
The board of directors of biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday declared a quarterly dividend of USD0.36 per share on the USD0.10 par value common stock.
